The ArgusCYTE Breast Health Test

The ArgusCYTE test is clinically proven, highly sensitive and informative, providing early warning about the presence of circulating breast cancer tumor cells (CTC) and molecular profiling of treatment target expression in a simple liquid biopsy specimen. Finding CTCs before metastatic disease is clinically apparent affords early treatment options.

ArgusCYTE can identify circulating cancer cells at the level of less than 10 cells/5mL of whole blood. The test can be applied at the time of diagnosis/biopsy or as a form of monitoring throughout therapy. ArgusCYTE enables the patient and healthcare provider to make more informed decisions about effective treatment options.

When a treatment decision is to be made, or as recurrence monitoring, the ArgusCYTE test identifies mRNA expression levels for estrogen receptors (ER), progesterone receptors (PR) and Her2 antigens.